Treatable traits protocol aims to reduce exacerbations in AECOPD patients
New trial to test personalized treatment for COPD flare-ups
This protocol describes a planned randomized controlled trial across 6 centers in China enrolling 314 patients with acute exacerbation of CO…
A new trial will test if personalized treatment based on 'treatable traits' can reduce COPD flare-ups and hospitalizations.
Early assessment at 4 weeks versus 8 weeks increases abstinence odds in tobacco users
Early Assessment May Improve Success Rates for Quitting Smoking
This randomized controlled trial of 636 daily smokers eligible for lung cancer screening found that a 4-week assessment interval was associa…
Checking progress at 4 weeks instead of 8 weeks may help people who smoke daily successfully quit using nicotine replacement therapy.
Low-dose N-acetylcysteine reduces acute exacerbation risk in patients with chronic obstructive pulmonary disease
N-acetylcysteine may reduce flare ups for people with COPD
This meta-analysis of randomized controlled trials involving 2,856 patients found that low-dose N-acetylcysteine (≤600 mg/day) significantly…
A specific dose of N-acetylcysteine could help lower the risk of sudden breathing problems for people living with chronic obstructive pulmon…
Polygenic risk scores and air pollutants associated with increased lung cancer risk
Genetic Scores and Air Pollution Linked to Lung Cancer Risk
This randomized controlled trial analyzed a cohort of 7,364 individuals to evaluate the impact of polygenic risk scores (PRS) and ambient ai…
New research shows that genetic risk scores and exposure to air pollutants are linked to higher lung cancer risk in a large screening group.
Health literacy-sensitive self-management programs improve exercise capacity and symptom burden in patients with COPD
Specialized self-management programs improve outcomes for people with COPD
This meta-analysis evaluated the impact of self-management interventions incorporating health literacy-sensitive components on adults with C…
New data shows that self-management programs designed to overcome health literacy barriers can improve walking distance and lung function fo…
Ensartinib improves 24-month disease-free survival to 86.4% in resected ALK-positive NSCLC
New drug shows promise for specific type of lung cancer
This Phase 3 randomized trial of 274 patients with resected, ALK-positive stage IB to IIIB NSCLC found that ensartinib (225 mg once daily) s…
A new medication called ensartinib significantly improved the time patients lived without their lung cancer returning after surgery.
Biologic therapies targeting T2 inflammatory pathways reduce exacerbation rates in COPD patients
Biologic Therapies Reduce Exacerbations in Specific COPD Patients
This meta-analysis evaluated biologic therapies targeting T2 inflammatory pathways in patients with COPD and biomarker-defined T2 inflammati…
New research shows that biologic therapies targeting specific inflammatory pathways can reduce severe flare-ups for patients with certain ty…
Organizational resilience and psychological support are key to improving ICU nurse teamwork during pandemics
Teamwork challenges and strengths for ICU nurses in COVID-19
This meta-synthesis of 48 qualitative studies examines the challenges and coping strategies of ICU nurses regarding team collaboration durin…
A review of 48 studies reveals what helped and hurt teamwork for ICU nurses during COVID-19.
Type-2 targeted biologics reduce moderate-to-severe exacerbations in patients with eosinophilic or type 2 COPD
New data shows how specific drugs reduce COPD flare ups
This systematic review and meta-analysis of placebo-controlled trials evaluates dupilumab, mepolizumab, and benralizumab for moderate-to-sev…
Specific targeted treatments show promise in reducing severe flare-ups for people with certain types of chronic lung disease.
Nivolumab plus chemotherapy improves pathological complete response in resectable NSCLC with PD-L1 < 1%
Nivolumab plus chemotherapy improves pathological response in certain lung cancers
This network meta-analysis of 1012 patients with resectable non-small cell lung cancer (NSCLC) and PD-L1 expression < 1% found that nivoluma…
A new analysis shows that adding nivolumab to chemotherapy can improve specific cancer responses for patients with low PD-L1 levels.
Aumolertinib Combined with Chemotherapy Improves Progression Free Survival in EGFR Mutated NSCLC
Combination therapy extends progression free survival in lung cancer
Phase 3 trial results show aumolertinib plus chemotherapy significantly extends progression-free survival compared to monotherapy for advanc…
A new trial shows that combining a specific drug with chemotherapy helps patients with advanced lung cancer live longer without their diseas…
Osimertinib treatment for EGFR-mutated NSCLC results in hypertension as the most common CVAE
Osimertinib treatment for lung cancer shows specific heart risks
This meta-analysis of 10,316 patients with EGFR-mutated non-small cell lung cancer evaluated cardiovascular adverse events (CVAEs) associate…
New data identifies hypertension as the most common heart-related side effect for patients taking osimertinib for certain types of lung canc…